A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.

CONTEXT Medication and cognitive behavioral treatment are the best-established treatments for social anxiety disorder, yet many individuals remain symptomatic after treatment. OBJECTIVE To determine whether combined medication and cognitive behavioral treatment is superior to either monotherapy or pill placebo. DESIGN Randomized, double-blind, placebo-controlled trial. SETTING Research clinics at Columbia University and Temple University. PARTICIPANTS One hundred twenty-eight individuals with a primary DSM-IV diagnosis of social anxiety disorder. INTERVENTIONS Cognitive behavioral group therapy (CBGT), phenelzine sulfate, pill placebo, and combined CBGT plus phenelzine. MAIN OUTCOME MEASURES Liebowitz Social Anxiety Scale and Clinical Global Impression (CGI) scale scores at weeks 12 and 24. RESULTS Linear mixed-effects models showed a specific order of effects, with steepest reductions in Liebowitz Social Anxiety Scale scores for the combined group, followed by the monotherapies, and the least reduction in the placebo group (Williams test = 4.97, P < .01). The CGI response rates in the intention-to-treat sample at week 12 were 9 of 27 (33.3%) (placebo), 16 of 34 (47.1%) (CBGT), 19 of 35 (54.3%) (phenelzine), and 23 of 32 (71.9%) (combined treatment) (chi(2)(1) = 8.76, P < .01). Corresponding remission rates (CGI = 1) were 2 of 27 (7.4%), 3 of 34 (8.8%), 8 of 35 (22.9%), and 15 of 32 (46.9%) (chi(2)(1) = 15.92, P < .01). At week 24, response rates were 9 of 27 (33.3%), 18 of 34 (52.9%), 17 of 35 (48.6%), and 25 of 32 (78.1%) (chi(2)(1) = 12.02, P = .001). Remission rates were 4 of 27 (14.8%), 8 of 34 (23.5%), 9 of 35 (25.7%), and 17 of 32 (53.1%) (chi(2)(1) = 10.72, P = .001). CONCLUSION Combined phenelzine and CBGT treatment is superior to either treatment alone and to placebo on dimensional measures and on rates of response and remission.

[1]  Cynthia L. Turk,et al.  Efficacy of a manualized and workbook-driven individual treatment for social anxiety disorder. , 2009, Behavior therapy.

[2]  R. Heimberg,et al.  Psychological Treatment of Social Anxiety Disorder and Specific Phobia , 2008 .

[3]  P. Cuijpers,et al.  Psychological treatment of social anxiety disorder: a meta-analysis , 2008, Psychological Medicine.

[4]  M. Schell,et al.  Sample size selection in clinical trials when population means are subject to a partial order: one-sided ordered alternatives , 2008 .

[5]  Jasper A. J. Smits,et al.  Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. , 2008, The Journal of clinical psychiatry.

[6]  A. Guastella,et al.  A Randomized Controlled Trial of D-Cycloserine Enhancement of Exposure Therapy for Social Anxiety Disorder , 2008, Biological Psychiatry.

[7]  Alan S. Brown,et al.  Growth trajectory during early life and risk of adult schizophrenia , 2007, British Journal of Psychiatry.

[8]  J. Davidson,et al.  An effect-size analysis of pharmacologic treatments for generalized anxiety disorder , 2007, Journal of psychopharmacology.

[9]  M. Liebowitz,et al.  The factor structure and screening utility of the Social Interaction Anxiety Scale. , 2006, Psychological assessment.

[10]  Naomi M Simon,et al.  Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. , 2006, Archives of general psychiatry.

[11]  C. Blanco,et al.  The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. , 2005, The Journal of clinical psychiatry.

[12]  Shyamal D. Peddada,et al.  ORIOGEN: order restricted inference for ordered gene expression data , 2005, Bioinform..

[13]  D. Kupfer,et al.  Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. , 2005, Archives of general psychiatry.

[14]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[15]  M. Liebowitz,et al.  A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. , 2005, The Journal of clinical psychiatry.

[16]  K. Gadde,et al.  Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. , 2004, Archives of general psychiatry.

[17]  M. Liebowitz,et al.  The evidence-based pharmacological treatment of social anxiety disorder. , 2003, The international journal of neuropsychopharmacology.

[18]  M. Liebowitz,et al.  Pharmacological treatment of social anxiety disorder: A meta‐analysis , 2003, Depression and anxiety.

[19]  Shyamal D. Peddada,et al.  Gene Selection and Clustering for Time-course and Dose-response Microarray Experiments Using Order-restricted Inference , 2003, Bioinform..

[20]  M. Liebowitz,et al.  Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder , 2003, Psychological Medicine.

[21]  I. Holme,et al.  Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial , 2003, British Journal of Psychiatry.

[22]  I. Holme,et al.  Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia , 2001, British Journal of Psychiatry.

[23]  J. Markowitz,et al.  A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. , 2000, The New England journal of medicine.

[24]  M K Shear,et al.  Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. , 2000, JAMA.

[25]  R. Kessler,et al.  Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey , 1999, Psychological Medicine.

[26]  M. Liebowitz,et al.  Factor structure of social fears: The Liebowitz Social Anxiety Scale. , 1999, Journal of anxiety disorders.

[27]  M. Liebowitz,et al.  Psychometric properties of the Liebowitz Social Anxiety Scale , 1999, Psychological Medicine.

[28]  D. Klein,et al.  Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. , 1998, Archives of general psychiatry.

[29]  R. Kessler,et al.  Social phobia subtypes in the National Comorbidity Survey. , 1998, The American journal of psychiatry.

[30]  R. Mattick,et al.  Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. , 1998, Behaviour research and therapy.

[31]  R. Heimberg,et al.  Factor structure of the Social Interaction Anxiety Scale and the Social Phobia Scale. , 1998, Behaviour research and therapy.

[32]  D J Kupfer,et al.  Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. , 1997, Archives of general psychiatry.

[33]  D. Sheehan,et al.  The measurement of disability. , 1996 .

[34]  R. Kessler,et al.  Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. , 1996, Archives of general psychiatry.

[35]  M. Liebowitz,et al.  Functional impairment in social phobia. , 1994, The Journal of clinical psychiatry.

[36]  J. Davidson,et al.  The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study , 1993, Psychological Medicine.

[37]  Debra A. Hope,et al.  Assessment of anxiety in social interaction and being observed by others: The social interaction anxiety scale and the Social Phobia Scale , 1992 .

[38]  M. Liebowitz,et al.  Pharmacotherapy of Social Phobia , 1992, British Journal of Psychiatry.

[39]  M. Weissman,et al.  Social Phobia: Comorbidity and Morbidity in an Epidemiologic Sample , 1992 .

[40]  J Gorman,et al.  Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. , 1992, Archives of general psychiatry.

[41]  M. Tancer,et al.  Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. , 1991, Archives of general psychiatry.

[42]  W. Agras,et al.  The assessment and treatment of performance anxiety in musicians. , 1991, The American journal of psychiatry.

[43]  Alan Agresti,et al.  Categorical Data Analysis , 2003 .

[44]  F. T. Wright,et al.  Order restricted statistical inference , 1988 .

[45]  J M Nam,et al.  A simple approximation for calculating sample sizes for detecting linear trend in proportions. , 1987, Biometrics.

[46]  Lloyd Gg,et al.  The treatment of social phobia. Real-life rehearsal with nonprofessional therapists. , 1981 .

[47]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[48]  Mark B. Powers,et al.  A Meta–Analytic Review of Psychological Treatments for Social Anxiety Disorder , 2008 .

[49]  Donald Hedeker,et al.  An Introduction to Growth Modeling , 2004 .

[50]  M. Liebowitz,et al.  Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. , 2002, Journal of anxiety disorders.

[51]  R. Heimberg.  Current status of psychotherapeutic interventions for social phobia. , 2001, The Journal of clinical psychiatry.

[52]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[53]  S. Zeger,et al.  Analysis of longitudinal data , 1994 .

[54]  A. Mathews,et al.  Brief standard self-rating for phobic patients. , 1979, Behaviour research and therapy.